(CercleFinance.com) – Novartis announces positive results from the primary analysis of ASC4FIRST, a pivotal phase III trial in the treatment of newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
According to this analysis, its Scemblix (asciminib) shows higher major molecular response (MMR) rates than standard tyrosine kinase inhibitors (TKIs) at week 48, meeting its primary endpoints.
Novartis adds that Scemblix demonstrated a favorable safety and tolerability profile with fewer adverse events and treatment interruptions compared to standard TKIs, and no new safety signals were observed.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
